| D007938 |
Leukemia |
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) |
Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias |
|
| D007939 |
Leukemia L1210 |
An experimental LYMPHOCYTIC LEUKEMIA of mice. |
Leukemia L 1210,L 1210, Leukemia,L1210, Leukemia |
|
| D008657 |
Metabolic Clearance Rate |
Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. |
Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance |
|
| D003561 |
Cytarabine |
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) |
Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C |
|
| D004334 |
Drug Administration Schedule |
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. |
Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration |
|
| D006801 |
Humans |
Members of the species Homo sapiens. |
Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man |
|
| D000208 |
Acute Disease |
Disease having a short and relatively severe course. |
Acute Diseases,Disease, Acute,Diseases, Acute |
|
| D000818 |
Animals |
Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. |
Animal,Metazoa,Animalia |
|
| D001085 |
Arabinofuranosylcytosine Triphosphate |
A triphosphate nucleotide analog which is the biologically active form of CYTARABINE. It inhibits nuclear DNA synthesis. |
Ara-CTP,Arabinosylcytosine Triphosphate,Cytarabine Triphosphate,Cytosine Arabinoside Triphosphate,Ara CTP,Triphosphate, Arabinofuranosylcytosine,Triphosphate, Arabinosylcytosine,Triphosphate, Cytarabine,Triphosphate, Cytosine Arabinoside |
|
| D001086 |
Arabinofuranosyluracil |
A pyrimidine nucleoside formed in the body by the deamination of CYTARABINE. |
Ara-U,Arabinosyluracil,Arauridine,Sponguridine,Uracil Arabinofuranoside,Uracil Arabinoside,1-beta-D-Arabinofuranosyl Uracil,NSC 68928,1 beta D Arabinofuranosyl Uracil,Ara U,Arabinofuranoside, Uracil,Arabinoside, Uracil,Uracil, 1-beta-D-Arabinofuranosyl |
|